No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 11.6x · 10Y median 18.9x · 20th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 23
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T14:16:17.392Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Caribou Biosciences, Inc. (CRBU) stock was $1.18 as of Oct 6, 2026, 10:15 AM EDT, down 1.26% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -47.4% · 3-year avg -36.2%/yr · 5-year avg -44.4%/yr
Caribou Biosciences, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to pioneering genome-edited allogeneic cell therapies.
Biotechnology · Berkeley, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 11, 2026
36 days away
EPS Estimate
-0.29
Revenue Est.
$2.12M
Last Quarter Results
EPS
$-0.24
vs Estimate
$-0.31
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CRBU | $116.54M | $1.18 | -1.26% | -47.42% | -44.43% | N/A | N/A |
| 2GNLX | $116.53M | $2.60 | -0.05% | -41.42% | N/A | N/A | vs CRBU |
| 3IMDX | $116.08M | $3.60 | -2.04% | +9.50% | -44.39% | -29.11% | vs CRBU |
| 4LENZ | $117.42M | $3.75 | +4.32% | -92.54% | -35.49% | N/A | vs CRBU |
| 5MXCT | $115.52M | $1.08 | -0.15% | -36.70% | -37.32% | N/A | vs CRBU |
| 6LUCD | $113.17M | $0.59 | -0.02% | -42.80% | N/A | N/A | vs CRBU |
forward FY estimate
N/A
$1.50M
vs Estimate
$2.28M
Consensus Rating
Based on 7 analysts
Average Price Target
$11.86
+909.1% upside
Low
$4.00
Current
$1.18
High
$32.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.32 | $-0.29 | $-0.26 | 3 |
| Quarter ending Dec 2026 | $-0.18 | $-0.17 | $-0.15 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-1.32 | $-0.95 | $-0.34 | 4 |
| FY 2027 | $-1.39 | $-1.28 | $-1.17 | 3 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $154475.00 | $2.12M | $5.94M | 3 |
| Quarter ending Dec 2026 | $1.14M | $22.54M | $43.94M | 4 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $1.93M | $10.70M | $19.47M | 4 |
| FY 2027 |
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| $6.59M |
| $12.25M |
| $28.56M |
| 3 |
